Loading clinical trials...
Loading clinical trials...
Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen
Conditions
Interventions
.Asunaprevir, Daclatasvir and BMS - 791325
Locations
1
France
France
All the Regions of the Country, France
Start Date
December 1, 2014
Primary Completion Date
November 1, 2015
Completion Date
August 1, 2016
Last Updated
February 2, 2016
Lead Sponsor
ANRS, Emerging Infectious Diseases
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions